



PEI Pharmacare
P.O. Box 2000
Charlottetown, PE
C1A 7N8
www.princeedwardisland.ca



Programmes provinciaux de médicaments
C.P. 2000
Charlottetown, PE
C1A 7N8
www.princeedwardisland.ca

PEI Pharmacare Bulletin

Issue (2025-12)

June 17, 2025

PEDIATRIC CLAIMS

Effective immediately, for Pharmacare patients who are 12 and under, and who are enrolled in programs where these medications are benefits, the following will not require a written Special Authorization:

- Lisdexamfetamine oral capsules and chewable tablets – for patients in Family Health Benefit Drug Program, Financial Assistance Drug Program, Catastrophic Drug Program
- Methylphenidate CR oral capsules – for patients in Family Health Benefit Drug Program, Financial Assistance Drug Program, Catastrophic Drug Program

Once a Pharmacare patient is over 12 but has already been established with Pharmacare coverage for the above medications, the dispensing pharmacy will have to contact the Pharmacare office to have coverage continued.

PEI BIOSIMILAR INITIATIVE REMINDERS

Ustekinumab (Stelara®)

- Patients with existing PEI Pharmacare coverage for Stelara® will need to switch to a biosimilar version before **August 31, 2025**, or by the renewal date of their current special authorization, whichever is earlier, to maintain coverage through PEI Pharmacare. A reminder that once a patient is switched to an ustekinumab biosimilar the annual reassessment of the patient and submission of a new Special Authorization Request Form is no longer required. (For patients newly starting on ustekinumab, the submission of an initial request and subsequent renewal will still be required; however, coverage will be set up long term thereafter assuming confirmation of continued response to therapy).

Denosumab (Prolia®)

- Patients with existing PEI Pharmacare coverage for Prolia® will need to switch to the biosimilar version before **August 31, 2025**, to maintain coverage through PEI Pharmacare. A new special authorization request for the biosimilar is not required.

A reminder that pharmacists may be reimbursed for a therapeutic substitution as outlined in the Professional Services Reimbursement Framework on the Resources for Community Pharmacies webpage at <https://src.healthpei.ca/resources-community-pharmacies>.